77
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Envelope Deglycosylation Enhances Antigenicity of HIV-1 gp41 Epitopes for Both Broad Neutralizing Antibodies and Their Unmutated Ancestor Antibodies

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The HIV-1 gp41 envelope (Env) membrane proximal external region (MPER) is an important vaccine target that in rare subjects can elicit neutralizing antibodies. One mechanism proposed for rarity of MPER neutralizing antibody generation is lack of reverted unmutated ancestor (putative naive B cell receptor) antibody reactivity with HIV-1 envelope. We have studied the effect of partial deglycosylation under non-denaturing (native) conditions on gp140 Env antigenicity for MPER neutralizing antibodies and their reverted unmutated ancestor antibodies. We found that native deglycosylation of clade B JRFL gp140 as well as group M consensus gp140 Env CON-S selectively increased the reactivity of Env with the broad neutralizing human mAbs, 2F5 and 4E10. Whereas fully glycosylated gp140 Env either did not bind (JRFL), or weakly bound (CON-S), 2F5 and 4E10 reverted unmutated ancestors, natively deglycosylated JRFL and CON-S gp140 Envs did bind well to these putative mimics of naive B cell receptors. These data predict that partially deglycoslated Env would bind better than fully glycosylated Env to gp41-specific naïve B cells with improved immunogenicity. In this regard, immunization of rhesus macaques demonstrated enhanced immunogenicity of the 2F5 MPER epitope on deglyosylated JRFL gp140 compared to glycosylated JRFL gp140. Thus, the lack of 2F5 and 4E10 reverted unmutated ancestor binding to gp140 Env may not always be due to lack of unmutated ancestor antibody reactivity with gp41 peptide epitopes, but rather, may be due to glycan interference of binding of unmutated ancestor antibodies of broad neutralizing mAb to Env gp41.

          Author Summary

          Critical to the design of an effective HIV-1 vaccine that will induce long-lasting broadly neutralizing antibodies is to understand why broad neutralizing antibodies are not induced. One hypothesis is that there are “holes” in the naïve B cell repertoires for unmutated B cell receptors that can bind to HIV-1 envelope (Env) neutralizing epitopes. In this paper, we test this hypothesis for the rare HIV-1 envelope gp41 broad neutralizing monoclonal antibodes (mAbs), called 2F5 and 4E10, and show that indeed, fully glycosylated Env does not bind to inferred unmutated ancestor antibodies (mimics of naïve B cell receptors) of mAbs 2F5 and 4E10, but that partially deglycosylated Envs that have had glycans removed under non-denaturing conditions, did bind to 2F5 and 4E10 unmutated ancestor antibodies. Thus, rather than there being a lack of existence of germline B cell receptors for gp41 broad neutralizing antibodies, one impediment to induction of gp41 broad neutralizing antibodies may be glycan interference with unmutated antibody binding to gp41 envelope.

          Related collections

          Most cited references53

          • Record: found
          • Abstract: found
          • Article: not found

          Molecular architecture of native HIV-1 gp120 trimers.

          The envelope glycoproteins (Env) of human and simian immunodeficiency viruses (HIV and SIV, respectively) mediate virus binding to the cell surface receptor CD4 on target cells to initiate infection. Env is a heterodimer of a transmembrane glycoprotein (gp41) and a surface glycoprotein (gp120), and forms trimers on the surface of the viral membrane. Using cryo-electron tomography combined with three-dimensional image classification and averaging, we report the three-dimensional structures of trimeric Env displayed on native HIV-1 in the unliganded state, in complex with the broadly neutralizing antibody b12 and in a ternary complex with CD4 and the 17b antibody. By fitting the known crystal structures of the monomeric gp120 core in the b12- and CD4/17b-bound conformations into the density maps derived by electron tomography, we derive molecular models for the native HIV-1 gp120 trimer in unliganded and CD4-bound states. We demonstrate that CD4 binding results in a major reorganization of the Env trimer, causing an outward rotation and displacement of each gp120 monomer. This appears to be coupled with a rearrangement of the gp41 region along the central axis of the trimer, leading to closer contact between the viral and target cell membranes. Our findings elucidate the structure and conformational changes of trimeric HIV-1 gp120 relevant to antibody neutralization and attachment to target cells.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.

            We present the crystal structure at 2.7 angstrom resolution of the human antibody IgG1 b12. Antibody b12 recognizes the CD4-binding site of human immunodeficiency virus-1 (HIV-1) gp120 and is one of only two known antibodies against gp120 capable of broad and potent neutralization of primary HIV-1 isolates. A key feature of the antibody-combining site is the protruding, finger-like long CDR H3 that can penetrate the recessed CD4-binding site of gp120. A docking model of b12 and gp120 reveals severe structural constraints that explain the extraordinary challenge in eliciting effective neutralizing antibodies similar to b12. The structure, together with mutagenesis studies, provides a rationale for the extensive cross-reactivity of b12 and a valuable framework for the design of HIV-1 vaccines capable of eliciting b12-like activity.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

              The design of a human immunodeficiency virus-1 (HIV-1) immunogen that can induce broadly reactive neutralizing antibodies is a major goal of HIV-1 vaccine development. Although rare human monoclonal antibodies (mAbs) exist that broadly neutralize HIV-1, HIV-1 envelope immunogens do not induce these antibody specificities. Here we demonstrate that the two most broadly reactive HIV-1 envelope gp41 human mAbs, 2F5 and 4E10, are polyspecific autoantibodies reactive with the phospholipid cardiolipin. Thus, current HIV-1 vaccines may not induce these types of antibodies because of autoantigen mimicry of the conserved membrane-proximal epitopes of the virus. These results may have important implications for generating effective neutralizing antibody responses by using HIV-1 vaccines.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS Pathog
                plos
                plospath
                PLoS Pathogens
                Public Library of Science (San Francisco, USA )
                1553-7366
                1553-7374
                September 2011
                September 2011
                1 September 2011
                : 7
                : 9
                : e1002200
                Affiliations
                [1 ]Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
                [2 ]Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America
                [3 ]Department of Chemistry, University of Kansas, Lawrence, Kansas, United States of America
                [4 ]Department of Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America
                [5 ]Deparment of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America
                [6 ]Center for Computational Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America
                [7 ]Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
                University of Zurich, Switzerland
                Author notes

                Conceived and designed the experiments: BFH HXL SMA NLL HD. Performed the experiments: BJM SMA EPG XZL CB LLS RMS SS GDT. Analyzed the data: BJM SMA HD TBK NLL HXL BFH. Contributed reagents/materials/analysis tools: BJM TBK HXL. Wrote the paper: HXL BJM BFH.

                Article
                PPATHOGENS-D-10-00417
                10.1371/journal.ppat.1002200
                3164629
                21909262
                224eeae9-38a5-4fce-9812-9467c5b449b0
                Ma et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
                History
                : 26 November 2010
                : 24 June 2011
                Page count
                Pages: 16
                Categories
                Research Article
                Biology
                Medicine

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article